What have studies with Herceptin for HER2-positive metastatic breast cancer found?
• A: Herceptin has been studied in a large clinical trial in people with HER2-positive metastatic breast cancer. People participating in the clinical trial received either chemotherapy plus Herceptin or chemotherapy alone. A clinical trial is a test of a treatment to see if it is beneficial to a particular group of people. If a treatment works well in an extensive clinical trial, it may become a new therapy that can help many people with cancer. In the Herceptin clinical trial, some people received chemotherapy plus Herceptin, while others received just chemotherapy. People who received Herceptin plus chemotherapy benefited in important ways. While results may vary, on average, people who received Herceptin plus chemotherapy: • Lived longer than those who received chemotherapy alone. • Their cancer was kept from growing for a longer time compared with those who received chemotherapy alone. • Their tumors shrank in size more often than those who received chemotherapy alone.Herceptin doe
Related Questions
- When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?
- How long should I continue therapy with Herceptin in the treatment of HER2-positive metastatic breast cancer?
- What have studies with Herceptin for HER2-positive metastatic breast cancer found?
